FDA approves Roche ’s Rituxan (rituximab) in children with two rare blood vessel disorders

Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan ® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients 2 years of age and older.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news